World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
102
Citations
79691
World Ranking
7475
National Ranking
3909

Overview

Michael F. Press is affiliated with the University of Southern California in the United States. Their research primarily focuses on biochemistry, genetics, and molecular biology, with a significant number of publications in medicine. The scientist's work extensively covers oncology, genetics, cancer research, molecular biology, and radiology, nuclear medicine, and imaging as subfields of study.

Their research topics include HER2/EGFR in cancer research, BRCA gene mutations in cancer, genetic associations and epidemiology, breast cancer treatment studies, cancer genomics and diagnostics, monoclonal and polyclonal antibodies research, and advanced breast cancer therapies.

Michael F. Press has contributed to the following recent papers:

  • Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials, 2021, The Lancet Oncology
  • ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer, 2023, Annals of Oncology
  • Deep learning-enabled breast cancer hormonal receptor status determination from base-level H&E stains, 2020, Nature Communications
  • Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100,800 women from 86 randomised trials, 2023, The Lancet
  • Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE, 2020, Journal of Clinical Oncology

Frequent co-authors of Michael F. Press include:

  • Esther M. John
  • Jennifer J. Hu
  • Barbara Nemesure
  • Christine B. Ambrosone
  • Wei Zheng

The scientist has published numerous papers in well-known venues, with frequent publications in:

  • UNC Libraries
  • Cancer Research
  • Annals of Oncology
  • Journal of Clinical Oncology
  • bioRxiv (Cold Spring Harbor Laboratory)

Best Publications

  • Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

    Dennis J. Slamon;William Godolphin;Lovell A. Jones;John A. Holt

  • American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

    Antonio C. Wolff;M. Elizabeth H. Hammond;Jared N. Schwartz;Karen L. Hagerty

  • Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

    Antonio C Wolff;M Elizabeth Hale Hammond;Kimberly H Allison;Brittany E Harvey

  • American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

    Antonio C. Wolff;M. Elizabeth H. Hammond;Jared N. Schwartz;Karen L. Hagerty

  • Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

    Antonio C. Wolff;M. Elizabeth H Hammond;David G. Hicks;Mitch Dowsett

  • Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

    Charles L. Vogel;Melody A. Cobleigh;Debu Tripathy;John C. Gutheil

  • Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

    Antonio C. Wolff;M. Elizabeth Hale Hammond;Kimberly H. Allison;Brittany E. Harvey

  • Adjuvant trastuzumab in HER2-positive breast cancer.

    Dennis Slamon;Wolfgang Eiermann;Nicholas Robert;Tadeusz Pienkowski

  • Estrogens, Progestogens, Normal Breast Cell Proliferation, and Breast Cancer Risk

    Malcolm C. Pike;Darcy V. Spicer;Laila Dahmoush;Michael F. Press

  • Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

    Stephen Johnston;John Pippen;Xavier Pivot;Mikhail Lichinitser

  • A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

    David Cameron;Michelle Casey;Michael Press;Deborah Lindquist

  • A Big Bang model of human colorectal tumor growth

    Andrea Sottoriva;Haeyoun Kang;Zhicheng Ma;Trevor A Graham

  • HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

    Michael F. Press;Leslie Bernstein;Patricia A. Thomas;Lorraine F. Meisner

  • Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.

    Michael F. Press;Carlos Cordon-Cardo;Dennis J. Slamon

  • Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.

    D. Slamon;W. Eiermann;N. Robert;T. Pienkowski

  • Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.

    Pauletti G;Godolphin W;Press Mf;Slamon Dj

  • Sensitivity of HER-2/neu Antibodies in Archival Tissue Samples: Potential Source of Error in Immunohistochemical Studies of Oncogene Expression

    Michael F. Press;Gene Hung;William Godolphin;Dennis J. Slamon

  • Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.

    Michael F. Press;Malcolm C. Pike;Victoria R. Chazin;Gene Hung

  • Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations

    Guido Sauter;James Lee;John M.S. Bartlett;Dennis J. Slamon

  • Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

    J Maltzman;Marck Pegram;Saeed Sadeghi;Cristina Oliva

Frequent Co-Authors

Esther M. John
Esther M. John Stanford University
Christopher A. Haiman
Christopher A. Haiman University of Southern California
Giske Ursin
Giske Ursin University of Oslo
Sue A. Ingles
Sue A. Ingles University of Southern California
Christine B. Ambrosone
Christine B. Ambrosone Roswell Park Cancer Institute
Dennis J. Slamon
Dennis J. Slamon University of California, Los Angeles
Wei Zheng
Wei Zheng Vanderbilt University Medical Center
Stephen J. Chanock
Stephen J. Chanock National Institutes of Health
Elisa V. Bandera
Elisa V. Bandera Rutgers, The State University of New Jersey
Jennifer J. Hu
Jennifer J. Hu University of Miami

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens the door to a variety of flexible, affordable online degree options. Many students and professionals are choosing cheap online fnp programs to become Family Nurse Practitioners without compromising quality or flexibility.

If you’re starting your nursing career, online nursing courses allow you to gain essential skills and credentials from home. For practicing RNs looking to advance, the cheapest rn to bsn online programs offer cost-effective pathways to enhance qualifications and earning potential.

For those with leadership ambitions, online phd nursing programs help you achieve the highest academic credentials, positioning you for roles in research, administration, and education.

These online pathways make it possible to balance your studies with work and family commitments, while keeping costs manageable—a critical consideration as you build your healthcare career.

Best Scientists Citing Michael F. Press

Trending Scientists

Recently Published Articles